Milvexian

Milvexian is a factor XIa inhibitor which acts as an anticoagulant. It is taken by mouth. As of late 2021, it was under study for the prevention of blood clots in patients undergoing surgery. In 2018–2023, Bristol-Myers Squibb studied milvexian for the prevention of stroke.